The Plasma Protein Therapeutics Association (PPTA) commends the Preserving Access to Orphan Drugs Acts, bipartisan legislation that makes an important policy clarification and will remove a barrier to research and development of rare disease therapies.
The Plasma Protein Therapeutics Association (PPTA) stands together with the global primary immunodeficiency disease (PID) community to promote World PI Week, a global campaign aimed to raise awareness and improve diagnosis and treatment of PID.
April 16, 2013–The Plasma Protein Therapeutics Association (PPTA) recognizes World Hemophilia Day, an annual international event sponsored by the World Federation for Hemophilia (WFH) that seeks to raise awareness of people living with inherited bleeding disorders.
The Plasma Protein Therapeutics Association (PPTA) applauds the House of Representatives on yesterday's passage of the Medicare IVIG Access Act (H.R. 1845), which gives Medicare patients who suffer from primary immunodeficiency disease (PID) better access to lifesaving intravenous immune globulin (IVIG) therapy at home.
PPTA presents at the 15th Biennial Meeting of the European Society of Immunodeficiencies (ESID 2012) held in collaboration with the International Patient Organisation of Patients with Immunodeficiency (IPOPI) and the International Nurses Group for Immune Deficiency (INGID).